Diamyd Results on Newly Diagnosed Type 1 Diabetes
Posted Apr 19th 2007 7:58AM by Allie Beatty
Filed under: Type 1, Childhood, Adult Onset, Drugs, Research
Diamyd showed promising results in slowing the attack on remaining islets in recently diagnosed type 1 diabetics. Diamyd is a therapy specifically designed to preserve residual beta cells in recently diagnosed type 1-diabetes.
The results from the Diamyd study demonstrated that the group of 35 recently diagnosed type 1-diabetes patients that received Diamyd produced approximately twice as much meal stimulated insulin, as measured by C-peptide levels. These results were present 15 months after the first treatment. Insulin and C-peptide are produced in equal amounts. As C-peptide is easier to measure, meal stimulated C-peptide levels is the most important parameter to follow in a type 1-diabetes study where the aim is to preserve beta cell function. C-peptide levels in both groups experienced a decline but the decline was significantly reduced in the Diamyd group. There were no significant differences in fasting C-peptide levels between the two groups.
There was no difference in HbA1c levels between the Diamyd group and the placebo group. This is consistent with type 1-diabetes patients striving to reach normal blood glucose levels through their standard insulin treatments. There was a tendency of increased GAD antibody levels in the Diamyd group, indicating that the drug candidate has an immunomodulating effect. Diamyd treated patients with disease duration of less than 3 months showed improved C-peptide levels at 15 months, whereas placebo treated patients showed a decline.
These results provide strong support that the administration of Diamyd is effective in preserving islet cell function in type 1-diabetes patients. Additionally, maintenance of endogenous insulin production is important as it helps patients to better control their disease and reduce long-term complications. There were no serious adverse events reported that were related to the Diamyd treatment.
Tags: ADA, adult onset type 1 diabetes, AdultOnsetType1Diabetes, American diabetes association, AmericanDiabetesAssociation, better control their diabetes, BetterControlTheirDiabetes, c peptide, change in average blood sugar, change in blood glucose levels, change in HbA1c, ChangeInAverageBloodSugar, ChangeInBloodGlucoseLevels, ChangeInHba1c, clinical trial results for diabetes, ClinicalTrialResultsForDiabetes, CPeptide, curing diabetes, CuringDiabetes, diabetes news, diabetes vaccine, DiabetesNews, DiabetesVaccine, diagnosed within 3 months, DiagnosedWithin3Months, diamyd, Diamyd Results on Newly Diagnosed Type 1 Diabetes, DiamydResultsOnNewlyDiagnosedType1Diabetes, effects lasted up to 15 months, EffectsLastedUpTo15Months, endogenous insulin production, EndogenousInsulinProduction, FDA clinical trials, FdaClinicalTrials, HbA1c, honeymoon period, HoneymoonPeriod, increased GAD antibody, IncreasedGadAntibody, increasing c-peptide, increasing natural insulin, IncreasingC-peptide, IncreasingNaturalInsulin, Insulin and C-peptide, InsulinAndC-peptide, JDRF, juvenile diabetes, JuvenileDiabetes, LADA diabetes, LadaDiabetes, meal stimulated insulin, MealStimulatedInsulin, measure of Insulin and C-peptide, MeasureOfInsulinAndC-peptide, National Institute of Health, NationalInstituteOfHealth, newly diagnosed diabetes, NewlyDiagnosedDiabetes, NIH, normal blood glucose levels, NormalBloodGlucoseLevels, phase 2 study, Phase2Study, preserve beta cell function, PreserveBetaCellFunction, preserving islets, PreservingIslets, promising results, PromisingResults, protecting islets, ProtectingIslets, recently diagnosed type 1 diabetics, RecentlyDiagnosedType1Diabetics, reduce diabetes complications, reduce long-term diabetic complications, ReduceDiabetesComplications, ReduceLong-termDiabeticComplications, role of Insulin and C-peptide, RoleOfInsulinAndC-peptide, slowing attack of islets, SlowingAttackOfIslets, study to preserve beta cell function, study to preserve islets, StudyToPreserveBetaCellFunction, StudyToPreserveIslets, type 1 diabetes, Type1Diabetes
1. "If you want my pledge to talk to people at Lilly and Novo about the potential promise of c-peptide, you have it".
The above is a quote from Matt P. at the ADA.
Has he called either or/and both Pharmaceutical Companies (Lilly and Novo-Nordisk about why was C-Peptide taken out of their Insulin Analogues?
Since C-Peptide has been shown to be Neuron-Protective and Membrane- Protective in Diabetes, it is a peptide that should be added or manufactured separately and made available for those with Diabetes.
Posted at 11:00AM on Apr 19th 2007 by BetterCell